MarketInOut Stock Screener Log In | Sign Up

Fusion Antibodies Plc

LSE • Healthcare • Biotechnology • Quote as of 10/27/2026 16:09
Fusion Antibodies Plc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeLSE
Market Capitalization6.88 mln
Float112 mln
Earnings Date12/07/2026

Piotroski F-Score

4 / 9
Borderline

Relative Strength

0 / 100
Severely lagging

Debt / Equity

0.20
Very low leverage

Pre-Tax Margin

-54%
Severely loss-making

ROE

-111
Deeply negative

Altman Z-Score

2.16
Borderline

Business Description

Founded in 2000 and headquartered in Belfast, Fusion Antibodies plc is a UK-based company that helps pharmaceutical, biotech, and life science organizations develop and produce specialized proteins and antibodies used to fight cancer and infectious diseases. The company provides a wide range of services, from discovering and refining antibodies to scaling up production under strict quality standards. It works with clients across Europe, North America, and beyond, and holds a collaboration agreement with the National Cancer Institute tied to its OptiMAL platform.

Key Fundamentals

EPS-1.00
ROE-111
RPS0.02
ROIC-264
ROA-57.95
Interest Cover-100
EBITDA, mln-1.00
EV / EBITDA-13.90
EV / EBIT-12.34
Revenue, mln2.11
EV / Revenue6.60

Quote Details

Last 5.94
Change 0.79 (15.34%)
Open 5.68
Volume 303,681
Turnover 1,803,865
Average Volume 724,902

Financial Ratios

Pre-Tax Profit Margin-54
Leverage Ratio1.68
Current Ratio2.82
Price / Book9.23
Price / Tangible Book12.00
Debt / Equity0.20
Price / Sales6.67

Financial Strength

Altman Z-Score2.16
Piotroski F-Score 4 / 9

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -5.26% 8 / 100   
1 Month -50.99% 0 / 100   
2 Months -42.16% 2 / 100   
6 Months -56.58% 2 / 100   
1 Year -55.51% 4 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog